645 Pancreatic Cancer Clinical Trials Recruiting Now (May 2026): Daraxonrasib, KRAS, Claudin 18.2, ADC, Immunotherapy
Last updated: May 30, 2026
🔔 Pre-ASCO 2026 (May 29 – June 2) update: The daraxonrasib (RMC-6236, pan-RAS(ON)) Phase 3 program in PDAC has expanded with NCT07491445 (RASolute 302) testing first-line monotherapy and combination with gemcitabine/nab-paclitaxel in metastatic disease — joining the previously-announced adjuvant resected trial NCT07252232 (RASolute 304). Updated RASolute Phase 1b/2 data and IBI343 (Claudin 18.2 ADC) G-HOPE-002 readouts are likely topics at ASCO 2026. See the drug landing pages for cross-tumor context.
Current Clinical Trial Landscape
Active research areas in 2026:
KRAS-targeted therapies (~65 trials) — pan-RAS inhibitors (daraxonrasib/RMC-6236 now in both first-line metastatic and adjuvant resected Phase 3), G12D-specific (RMC-9805, HRS-4642), G12C inhibitors (sotorasib), G12V TCR-T cell therapy, KRAS neoantigen vaccines
Standard of care: For resectable disease: surgery followed by adjuvant modified FOLFIRINOX (6 months) or gemcitabine + capecitabine. Neoadjuvant chemotherapy increasingly used for borderline resectable. For locally advanced: FOLFIRINOX or gemcitabine/nab-paclitaxel, with radiation in selected cases. For metastatic: FOLFIRINOX (fit patients) or gemcitabine/nab-paclitaxel. Olaparib maintenance for germline BRCA1/2-mutated patients with platinum-stable/responsive disease (POLO trial). Second-line: nanoliposomal irinotecan + 5-FU/leucovorin (NAPOLI-1).
Key Biomarkers for Trial Eligibility
Molecular profiling is essential — over 25% of pancreatic cancer patients have actionable mutations:
KRAS mutation type — present in ~90% of PDAC. The specific variant matters for targeted therapy:
KRAS G12D (~40%) — most common; RMC-9805, HRS-4642 trials
KRAS G12V (~30%) — IX001 TCR-T cell therapy trial
KRAS G12C (~1-2%) — sotorasib (FDA-approved for NSCLC, trials in PDAC)
BRCA1/2 or PALB2 mutation — germline mutations in ~5-7%. Eligible for platinum-based chemo (better response), PARP inhibitors (olaparib), and specific combination trials.
MSI-H / dMMR — rare (~1-2%) but eligible for pembrolizumab (FDA-approved for all MSI-H cancers). Dramatic responses possible.
Claudin 18.2 (CLDN18.2) expression — expressed in ~60% of PDAC. Target for IBI343 ADC (Phase 3) and CAR-T therapy.
NTRK fusion — very rare (<1%) but druggable with larotrectinib or entrectinib (FDA-approved).
HER2 amplification — rare (~2-3%) but eligible for trastuzumab deruxtecan and other HER2 ADC trials.
ctDNA (circulating tumor DNA) — increasingly used to guide adjuvant therapy decisions. Several trials use ctDNA to identify patients who may benefit from additional treatment after surgery.
Know your KRAS variant and BRCA status? Get matched to pancreatic cancer trials in minutes.
FOLFIRINOX or gemcitabine/nab-paclitaxel remain standard. Trials add novel agents:
Pan-RAS / KRAS-directed first-line:
NCT07491445 - RASolute 302: Daraxonrasib (RMC-6236) monotherapy and daraxonrasib + Gemcitabine/Nab-paclitaxel vs SOC in first-line metastatic PDAC (Phase 3, the registrational metastatic-setting trial of the pan-RAS(ON) inhibitor)
NCT07562152 - Atebimetinib + Gemcitabine/Nab-paclitaxel as first-line treatment in metastatic PDAC (Phase 3 MEK inhibitor combo)
NCT06250972 - Radiotherapy for CA19-9-elevated advanced PDAC (Phase 3)
KRAS-Targeted Therapies (~65 trials)
Over 90% of pancreatic cancers have KRAS mutations. Once considered undruggable, KRAS is now a therapeutic target — daraxonrasib (RMC-6236) is the first pan-RAS(ON) inhibitor to enter Phase 3 in PDAC, in both the first-line metastatic and adjuvant-resected settings simultaneously:
HER2-targeted (HER2-amplified PDAC):trastuzumab deruxtecan (T-DXd) pan-tumor HER2 ADC program; HER2 expression occurs in ~2-3% of PDAC and qualifies for T-DXd and other HER2 ADC trials
Cancer cachexia (supportive care):NCT06989437 - Ponsegromab (GDF-15 antagonist) in PDAC patients with cachexia (Phase 3) — first dedicated cachexia Phase 3 for PDAC
ctDNA-guided:NCT05482516 - Novel therapies in ctDNA-positive GI cancers
Intra-arterial chemotherapy: Direct hepatic artery or tumor infusion to overcome poor drug delivery in PDAC
How do I find pancreatic cancer clinical trials I'm eligible for?
Enter your pancreatic cancer details into ClinTrialFinder — including KRAS mutation type (G12D, G12V, G12C, G12R), BRCA/PALB2 status, disease stage (resectable, borderline, locally advanced, metastatic), and prior treatments. The AI matches you with trials based on your specific profile in minutes. No login required.
What pancreatic cancer trials are currently recruiting?
There are 645 recruiting interventional trials for pancreatic cancer in May 2026, including pan-RAS daraxonrasib (RMC-6236) in both first-line metastatic (RASolute 302, NCT07491445) and adjuvant resected (RASolute 304, NCT07252232) Phase 3 trials, KRAS G12D-specific therapies (RMC-9805, HRS-4642), G12V TCR-T cell therapy, KRAS vaccines, Claudin 18.2-targeted ADCs (IBI343 G-HOPE-002 Phase 3) and CAR-T, BRCA/PALB2-directed PARP and platinum regimens, MSI-H immunotherapy, tumor treating fields, ponsegromab for cachexia, and ctDNA-guided adjuvant therapy.
Should I get molecular profiling for pancreatic cancer?
Yes — comprehensive genomic profiling is strongly recommended for all pancreatic cancer patients. Over 25% have actionable mutations: BRCA1/2 or PALB2 (~5-7%) qualify for PARP inhibitors and platinum-based therapy, MSI-H (~1-2%) responds dramatically to immunotherapy, NTRK fusions are druggable with FDA-approved agents, and knowing your specific KRAS variant (G12D, G12V, G12C) determines which targeted therapy trials you're eligible for.
Are KRAS-mutant pancreatic cancers now treatable with targeted therapy?
KRAS — once considered "undruggable" — is now a therapeutic target. Daraxonrasib (RMC-6236), a pan-RAS(ON) inhibitor, is in two registrational Phase 3 trials in PDAC simultaneously: first-line metastatic monotherapy and combination with gemcitabine/nab-paclitaxel (RASolute 302, NCT07491445), and adjuvant after surgical resection (RASolute 304, NCT07252232). RMC-9805 targets KRAS G12D specifically (the most common variant in pancreatic cancer, ~40%). KRAS G12C can be targeted with sotorasib. KRAS vaccines and TCR-T cell therapy targeting G12V are also in clinical trials. Knowing your specific KRAS variant is essential.
Find Pancreatic Cancer Trials Matched to Your Situation
Enter your KRAS mutation type, BRCA status, and disease stage to get AI-matched trial results in minutes.
This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.
